Tag: Abivax
Abivax: 261 million in cash, visibility until the end of 2025
(AOF) – Abivax (+1.19% to 13.56 euros) is up after the announcement of its results. The biotech announces a cash position of 261 million euros at the end of 2023,…
Abivax publishes its 2023 annual results and presents a progress update on the activity. – 02/04/2024 at 08:35
ABIVAX press release Abivax publishes its 2023 annual results and presents a progress update on the activity. • Financing of 500 million euros in 2023, including a capital increase of…
Abivax: Appointment of a quality manager
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Ana Sharma appointed Vice President, Global Head of Quality at Abivax – 02/07/2024 at 08:31
PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic…
Abivax: the stock advances after an update on strategy – 01/22/2024 at 10:49
(CercleFinance.com) – Abivax is making progress on the Paris Stock Exchange this Monday after taking stock of its strategic prospects for 2024, as well as the main milestones to be…
Abivax optimistic about its prospects – 01/22/2024 at 11:56
(AOF) – Abivax (+0.78% to 10.38 euros) has positive prospects, three months after its introduction to the Nasdaq last October, which allowed it to raise a gross amount of 235.8…
Abivax: the title advances after an update on strategy
(CercleFinance.com) – Abivax is making progress on the Paris Stock Exchange this Monday after taking stock of its strategic prospects for 2024, as well as the main milestones to be…
Abivax: Sofinnova Partners falls below 10% of votes
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Abivax announces the completion of its IPO on the Nasdaq Global Market. – 10/24/2023 at 10:10 p.m.
ABIVAX press release Abivax announces the completion of its IPO on the Nasdaq Global Market. Abivax SA “Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of…
Abivax: setting of the introduction price on the Nasdaq Global Market
By Jean-Noël Legalland Published on 10/20/2023 at 3:06 p.m. Photo credit © Abivax (Boursier.com) — Abivax announces the…
Abivax: trading can resume
By Jean-Noël Legalland Published on 10/20/2023 at 4:09 p.m. Photo credit © Abivax (Boursier.com) — Abivax announces the…
Abivax: difficult start for the biotech on the Nasdaq – 10/20/2023 at 4:47 p.m.
(CercleFinance.com) – Abivax lost more than 14% on Friday for its first steps on the Nasdaq, reflecting both the current difficult market conditions and the recent lack of investor interest…